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ABSTRACT: Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is the infectious disease responsible for the highest
number of deaths worldwide. Herein, 22 new N-oxide-containing compounds were synthesized followed by in vitro and in vivo
evaluation of their antitubercular potential against Mtb. Compound 8 was found to be the most promising compound, with
MIC90 values of 1.10 and 6.62 μM against active and nonreplicating Mtb, respectively. Additionally, we carried out in vivo
experiments to confirm the safety and efficacy of compound 8; the compound was found to be orally bioavailable and highly
effective, leading to a reduction of Mtb to undetectable levels in a mouse model of infection. Microarray-based initial studies on
the mechanism of action suggest that compound 8 blocks translation. Altogether, these results indicate that benzofuroxan
derivative 8 is a promising lead compound for the development of a novel chemical class of antitubercular drugs.
■ INTRODUCTION
Mycobacterium tuberculosis (Mtb), the causative agent of tuber-
culosis (TB) in humans, is considered to be responsible for the
highest number of deaths caused by an infectious disease world-
wide in 2015. The World Health Organization (WHO) reported
9.6 million new cases and 2 million deaths worldwide in the same
year.1 The high mortality rate of TB has even surpassed the
number of deaths caused by human immunodeficiency virus.
According to an estimate, one-third of the world’s population is
infected with a latent form of TB,2 for which treatment is often
ineffective owing to a lack of drugs with the ability to act on
mycobacteria in the dormant state.3,4
Furthermore, the increased dissemination of multidrug-
resistant (MDR), extensively drug-resistant, and totally drug-
resistant strains has posed a huge challenge throughout the world
in the fight against TB.5−8
For treating TB, the WHO recommends a combination of
isoniazid (INH), rifampicin (RMP), ethambutol, and pyrazina-
mide for 6 months. For cases involving resistance, the treatment
can be extended up to 28 months and include the use of second-
line drugs, such as fluoroquinolones, aminoglycosides, D-cycloserine,
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and linezolid, among others.9−11 The current treatment suffers
from several limitations, including the prolonged standard
regimen, the high rate of treatment discontinuation, adverse
effects, toxicity, drug−drug interactions, and a lack of effective-
ness against the latent mycobacteria.2,12−16
Over the past few years, limited but significant progress in the
development of drug candidates against TB has been achieved.
After a gap of more than 50 years without new drugs approved for
TB, the United States Food and Drug Administration approved
bedaquiline (Bdq, SIRTURO, Janssen; Beerse, Belgium) in 2012
for the treatment of MDR-TB. The literature over the past
5 years has indicated significant advances in the development of
other compounds with potent antitubercular activity.17−20 In this
regard, several drug candidates were moved toward clinical trials,
such as sutezolid, posizolid, delamanid, and pretomanid.21,22
Nevertheless, Mtb strains resistant to the new compounds have
already been reported,23−25 reinforcing the urgency to develop
more potent and a larger number of novel drugs for the treatment
of TB.11
We previously reported a series of furoxan derivatives with
potent activity against Mtb, including MDR strains. Specifically,
the compound (E)-4-(4-((2-isonicotinoylhydrazono)methyl)-
phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide (Figure 1)
inhibited the growth of Mtb strain H37Rv by 90% at a concen-
tration of 1 μM. In addition, we determined that the antitubercular
activity of this furoxan derivative was related to its ability to
generate nitric oxide (NO) following biotransformation.26
Motivated by preliminary promising results obtained with the
furoxan derivatives, we designed new heterocyclic analogues con-
taining the N-oxide subunit, including amide-furoxans (series 1),
benzofuroxans (series 2), and quinoxaline 1,4-di-N-oxide
(QdNO) (series 3, Figure 1). Furoxans, benzofuroxans, and
QdNO derivatives represent important scaffolds in medicinal
chemistry due to their wide spectrum of biological activities,27
including antitubercular activity.28 The antimycobacterial activity
of these compounds is attributed to the generation of reactive
oxygen species (ROS) following their biotransformation.29−31
For quinoxalines specifically, earlier studies have reported that
these compounds lead to increased levels of ROS under hypoxic
conditions, which could contribute to interesting properties
against latent TB.32−34
ROS play a crucial role in the pathogenesis of TB. Several
studies have demonstrated the relationship between the level of
ROS produced by immune cells and the susceptibility of a patient
to several species of theMycobacterium genus.35,36 Furthermore,
the effects exerted by ROS during TB are many-fold. For example,
increased ROS levels can lead to inhibition ofMtb growth, damage
to cellular components, such as lipids, proteins, and nucleic acids,
and activation ofmacrophage-mediated inflammatory activity.37−40
High levels of ROS can also induce apoptosis of macrophages
(host for tubercle bacilli), thereby preventing the growth and
replication of the bacilli.41 Therefore, the design of new com-
pounds that could act by increasing the levels of ROS and
perturbing mycobacterial redox homeostasis seems to be a
promising strategy for combating TB.42−44
In a continuing effort to develop new drug candidates for the
treatment of TB, we herein describe the design, synthesis, and
biological activities of a series of heterocyclic compounds
containing N-oxide as antitubercular compounds.
■ RESULTS AND DISCUSSION
Chemistry. Twenty-two novel compounds containing the
N-oxide subunit were synthesized according to the synthetic
methodologies presented in Schemes 1, 2, and 3.
Amide-furoxan derivatives 1 and 2 were synthesized according
to previously described methods.45,46 Furoxan derivative 2 was
allowed to react with 2-, 3-, or 4-hydroxybenzaldehyde in
dichloromethane, using 1,8-diazabicyclo[5.4.0]undec-7-ene
(DBU) as the base, leading to the formation of furoxan derivatives
containing an aldehyde group (3a−c).47 Then, a condensation
reaction of the aldehyde derivatives with isonicotinohydrazide
was performed in ethanolic medium catalyzed by an acid to
generate hybrid furoxan derivatives 4a−c (Scheme 1).
The benzofuroxan derivative containing an aldehyde group (7)
was obtained according to a previously reported methodology.48
Figure 1. Design of the N-oxide-containing heterocycle derivatives.
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The compound was allowed to react with different aromatic
hydrazides through the same condensation reaction described
above, leading to the formation of benzofuroxan derivatives 8−
17 (Scheme 2). The 1H and 13C nuclear magnetic resonance
(NMR) spectra of these compounds displayed proton and
carbon signals from the benzofuroxan nucleus as broad peaks,
indicating benzofuroxan tautomerism.27,31
Dioxolan-benzofuroxan derivative 18was obtained from the reac-
tion between compound 7 and ethylene glycol.49 The quinoxaline
derivatives were obtained through a variation of the Beirut
reaction,50−52 wherein dioxolan-benzofuroxan derivative 18 was
reacted with the appropriate nitrile derivatives in dichlorometh-
ane. Potassium carbonate (K2CO3) was utilized as a catalyst,
53
leading to the generation of quinoxaline derivatives 19−26.
Compound 28 was synthesized from quinoxaline 19, which
was submitted to cyclic acetal hydrolysis followed by its reac-
tion with isonicotinohydrazide through a condensation reaction
(Scheme 3).54
Scheme 2. Preparation of the Compounds of Series 2a
aReagents and conditions: (a) NaN3, DMSO, 75 °C, 1 h; (b) toluene, reflux, 2 h; (c) aromatic hydrazide, ethanol, acetic acid, rt, 12 h.
Scheme 3. Preparation of the Compounds of Series 3a
aReagents and conditions: (a) toluene, ethylene glycol, p-toluenesulfonic acid, reflux, 12 h; (b) DCM, K2CO3, 40 °C, 96 h; (c) acetone, HCl, rt,
48 h; (d) isonicotinohydrazide, ethanol, acetic acid, rt, 12 h.
Scheme 1. Preparation of the Compounds of Series 1a
aReagents and conditions: (a) thionyl bromide, DMF, rt, 30 min; (b) DBU, 2, 3, or 4-hydroxybenzaldehyde, DCM, rt, 1 h; (c) ethanol, acetic acid,
rt, 12 h.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01332
J. Med. Chem. 2017, 60, 8647−8660
8649
All compounds were characterized by elemental analysis,
infrared (IR) spectroscopy, mass spectrometry, and 1H and 13C
NMR. Furthermore, all compounds were analyzed by high-
pressure liquid chromatography (HPLC), and their purity was
confirmed to be greater than 98.5%. Experimental logP values
and melting points were determined for the final compounds.
Biological Studies. The antitubercular activity of com-
pounds containing N-oxide (4a−c, 8−17, 19−26, and 28) was
assessed usingMtb strain H37Rv (ATCC 27294). The Resazurin
microtiter assay (REMA) was employed as described pre-
viously.26,55 The results are expressed as minimum inhibitory
concentration (MIC90), and compounds showing MIC90 values
below 10 μM were selected for further characterization.
The potential cytotoxicity of the compounds was evaluated
using the MRC-5 human lung fibroblast cell line according
to a previously reported methodology,26,56 and the results are
expressed as IC50 values. The selectivity index (SI) of the tested
compounds was calculated through the ratio of IC50 to MIC90.
The compounds that reported SI≥ 10 were considered promising
for further studies according to the cutoff value established.56,57
Potential anaerobic activity of the best compounds was evaluated
using the method described by Cho et al.58
Analysis of the spectrum of biological activities of the com-
pounds was performed through determination of MIC90 values
against Escherichia coli (ATCC 25922) and Staphylococcus aureus
(ATCC 29213) by measuring the optical density (OD) at
570 nm (OD570) after 16 h and against Candida albicans (ATCC
10231) at OD570 after 48 h.
The compounds were also tested against isogenic Mtb H37Rv
strains monoresistant to RMP (ATCC 35838), INH (ATCC
35822), streptomycin (SM, ATCC 35820), capreomycin (CAP),
moxifloxacin (MOX), and BDQ (strains were from the
University of Illinois at Chicago Institute for Tuberculosis
Research) by the multiple antigen blot assay (MABA) micro-
dilution technique.59 Following this step, we selected the best
compound (compound 8) for further studies.
Due to the ability of Mtb to survive inside macrophages,
we decided to investigate whether compound 8 could inhibit the
growth ofMtb strain H37Rv in the J774A.1 macrophage cell line.
Furthermore, time−kill experiments were performed for up to
15 days to evaluate the bactericidal profile of compound 8.
Some earlier reports60,61 indicated that the growth of myco-
bacteria can be affected by the presence of ions and nutrients as
well as by the pH of themedium. For this reason, different culture
medium conditions were analyzed by MABA. These included
(a) adjusting the culture medium to pH 6.0, (b) including 4%
bovine serum albumin (BSA), and (c) supplementing with 10%
fetal bovine serum (FBS). The slightly acidic pH (pH 6.0) was
selected because it is compatible with the growth of Mtb and
corresponds to that at the time whenMtb-containing phagosomes
fuse with lysosomes.One of the physiological functions of albumin
(synthesized in the liver) is to transport poorly soluble molecules
of both endogenous and exogenous origins.62 Albumin binding
constitutes an essential pharmacological parameter that affects
the mechanism of action (MOA) of antibiotics in humans.63
We utilized FBS, as it serves as a growth factor for mammalian
cells and might interfere with the antitubercular action of some
compounds.
Preliminary ADMT (absorption, distribution, and metabolism)
studies were performed for compound 8 using the follow-
ing in vitro assays: chemical stability, plasma protein binding,
caco-2 permeability, cytochrome P450 inhibition, and hepG2
cytotoxicity. Additionally, we characterized the mutagenicity of
compound 8 through a micronucleus assay using mouse
peripheral blood reticulocytes.
To ensure greater stability and improved solubility, com-
pound 8 was evaluated in an in vivo assay using a pharmaceutical
formulation. The nanostructured lipid system (ME) was synthe-
sized as described by our group previously,64 with the following
composition: 10% oil phase (cholesterol), 10% surfactant (a mix-
ture of soy phosphatidylcholine, sodium oleate, and Eumulgin
HRE 40 [polyoxyl 40 castor oil-hydrogenated]; 3:6:8), and 80%
aqueous phase (phosphate buffer, pH 7.4). The compounds
studied were incorporated at the desired concentration for the
in vivo experiments by mass solubilization at the respective
volume and sonicated for 3 min in batch mode at 15% amplitude.
The ME-containing compound 8 was analyzed for tolerability
and oral bioavailability following the treatment of female BALB/C
mice infected with Mtb.
Microarrays have been used to successfully define the MOA of
antitubercular compounds.65 Therefore, a microarray analysis
was performed to obtain an unbiased view of the MOA of
compound 8.
In Vitro Antimycobacterial Activity. The ability of Mtb to
remain dormant serves as the predominant factor that
contributes to precluding sterilization with antibiotic therapy
and promotes the development of antibiotic resistance.66,67
Therefore, an ideal antitubercular drug should (i) reduce the
duration of treatment, (ii) be active against resistant strains,
(iii) not interfere with other TB drugs and antiretrovirals, and
(iv) be active against “dormant” bacilli.10
Recently, our research group identified the compound (E)-4-
(4-((2-isonicotinoylhydrazono)methyl)phenoxy)-3-(phenylsul-
fonyl)-1,2,5-oxadiazole 2-oxide as a promising antitubercular
drug candidate.26 To optimize its antimycobacterial activity,
we designed novel heterocyclic compounds containing N-oxide
analogues of the parent compound, which comprised the follow-
ing heterocyclic moieties: amide-furoxan (series 1, 4a−c),
benzofuroxan (series 2, 8−17), and quinoxaline 1,4-di-N-oxide
(series 3, 19−26 and 28). The amide-furoxan derivatives (4a−c)
were selected to evaluate whether the replacement of the phenyl-
sulfonyl group from the parent compound by an amide group
would increase the antitubercular activity and/or decrease the
cytotoxicity. The three amide-furoxan regioisomers (4a−c)
displayed improved antitubercular activity compared to that of
the parent compound.26 The compounds from series 1 exhibited
MIC90 values around 0.4 μM against actively growingMtb strain
H37Rv (Table 1).
The benzofuroxan moiety (series 2, 8−17) was selected due
to its possible ability to generate ROS after its metabolism.30
The structural design of the series under study was based
on the isosteric replacement of substituents attached on the
phenyl ring. These included hydrogen, nitro, tert-butyl, amino,
and hydroxyl groups. Furthermore, we evaluated the substitu-
tion of the phenyl ring by a pyridine ring owing to the presence
of a heterocyclic pyridine ring in the structure of several anti-
tuberculosis drugs and bioactive compounds, such as INH,
BDQ, and ethionamide.68 As expected, the replacement of the
phenyl ring of compound 9 by a pyridine ring in compound 8
led to a 7-fold increase in the antituberculosis activity (MIC90 =
1.1 μM; Table 1).
Among the benzofuroxan series, our group identified the
compound (E)-6-((2-isonicotinoylhydrazono)methyl)benzo-
[c][1,2,5]oxadiazole 1-oxide (8) as the lead benzofuroxan
derivative with MIC90 values of 1.1 and 6.6 μM against actively
growing and dormant Mtb, respectively. The nearly equimolar
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effects observed against replicating and nonreplicating Mtb,
suggested by the small difference in MIC90 values, is considered
to be an attractive characteristic. Such differences are rarely
observed but highly desired and beneficial.
Moreover, our data revealed that the presence of bulky groups,
such as tert-butyl (10, MIC90 = 3.9 μM), and electron-
withdrawing groups, such as nitro (11, MIC90 = 5.3 μM), led
to an improvement in antituberculosis activity of the analyzed
compounds. Compound 9 (unsubstituted phenyl) presented
an MIC90 value of 8.3 μM, whereas the hydroxyl regioisomers
(12−14) presented MIC90 values greater than 62 μM. Amino
derivatives 15−17 also exhibited a reduction in antitubercular
activity in comparison to that of nonsubstituted compound 9;
however, these compounds reportedMIC90 values (12.3−27.9μM)
lower than those containing a hydroxyl substitution (Table 1).
With respect to the quinoxaline 1,4-di-N-oxide series, we
evaluated the influence of electron-withdrawing and electron-
donating groups on the phenyl ring on antitubercular activity.
We also performed an isosteric substitution of the phenyl ring by
furan (25) and thiophen (26) moieties. For quinoxaline-phenyl
derivatives 19−24, the MIC90 values ranged from 12.0 to
30.8 μM, implying a contribution of the presence of substitution
at the para position of the phenyl ring to the antituberculosis
activity. Since compound 19 was devoid of any substituents,
it displayed a lower potency among the phenyl quinoxaline
derivatives with an MIC90 of 30.8 μM. On the other hand,
compound 22, with a methoxyl group in the para position,
displayed the lowest MIC90 value among the phenyl quinoxaline
series. Nevertheless, we could not observe a clear and accurate
structure−activity relationship with regard to the electronic
properties of the substituents.
For compounds 25 and 26, the isosteric replacement of the
phenyl group by a furan or thiophen ring led to a significant
increase in the antitubercular activity. Compounds 25 and 26
exhibitedMIC90 values of 5.2 and 12.1 μM, respectively. Further-
more, we synthesized a quinoxaline derivative containing an
N-acylhydrazone subunit (28); the antitubercular activity of this
compound decreased in comparison to that of the previous
quinoxalines, exhibiting an MIC90 value of 39.7 μM.
Further in Vitro Biological Profiling of Selected
Compounds. We evaluated the cytotoxicity of the final
compounds against the MRC-5 cell line. This cell line is derived
from healthy human lung fibroblasts and is widely utilized for the
phenotypic screening of antitubercular drugs.69−71
The data obtained in the cytotoxicity studies of the amide-
furoxan series (4a−c) indicated a high selectivity of these com-
pounds against Mtb. All three regioisomers exhibited high
IC50 values (>854.0 μM), thereby leading to high SI values, which
ranged from 2033 to 3205 (Table 1).
Regarding the cytotoxicity studies of the benzofuroxan series,
we observed IC50 values ranging from 25 to 841 μM against the
MRC-5 cell line. The most active benzofuroxan derivative (8)
presented an IC50 value of 519 μM; however, compound 17 was
found to be less cytotoxic among the benzofuroxan series with an
IC50 value of 841 μM. Compounds 11−14 did not display
promising antitubercular activity (MIC90 > 62 μM) and conse-
quently were excluded from the cytotoxicity studies. Rather,
compound 8 was selected for further experiments as it possessed
the highest potency against Mtb and the lowest cytotoxicity.
Compounds from the quinoxaline series were significantly
more cytotoxic against MRC-5 cells, with IC50 values ranging
Table 1. Antitubercular Activity of N-Oxide-Containing Heterocycles against Actively Replicating and Dormant M. tuberculosis
H37Rv (MIC90), Cytotoxicity against the MRC-5 Cell Line (IC50), Selectivity Index (SI), and Experimental LogP
MIC90 dormant MIC90 cytotoxicity IC50
class compound μg/mL μM μg/mL μM μg/mL μM SIa LogPb
furoxan 4a 0.16 0.42 2.95 7.72 326.70 854.00 2033.30 1.3
4b 0.15 0.40 1.60 4.20 490.10 1281.90 3204.70 1.3
4c 0.16 0.43 0.78 2.04 443.30 1159.50 2696.50 1.3
benzofuroxan 8 0.31 1.10 − 6.62 147.10 519.20 472.0 1.5
9 2.40 8.30 − − 36.80 130.40 15.60 2.2
10 1.30 3.90 − − 8.50 25.20 6.30 3.8
11 1.73 5.29 − − − − − 0.9
12 16.40 >62.0 − − − − − 1.3
13 >25.0 >62.0 − − − − − 1.2
14 >25.0 >62.0 − − − − − 1.2
15 3.70 12.30 − − 36.40 122.40 9.90 2.0
16 5.30 17.80 − − 24.40 82.10 4.60 1.4
17 3.16 10.66 >10.0 >10.0 250.0 841.0 78.90 1.2
quinoxaline 19 10.30 30.80 − − 10.70 31.90 0.90 0.7
20 5.70 16.50 − − 6.20 17.20 1.10 1.6
21 6.40 16.20 − − 5.00 12.60 0.80 1.8
22 4.40 12.00 − − 5.50 15.00 1.20 1.4
23 8.60 24.30 − − 7.70 21.80 0.90 1.3
24 6.50 15.40 − − 28.00 66.80 4.30 2.2
25 1.70 5.20 − − 11.60 35.70 6.80 2.0
26 4.10 12.10 − − 5.90 17.30 1.40 1.9
28 16.30 39.70 − − 8.60 21.00 0.50 1.0
standard drugs isoniazid 0.014 0.1 − 1.108.4 − − − −
rifampicin 0.082 0.1 − 0.1 N.D. N.D. N.D. N.D.
aSI indicates the ratio between the IC50 against MRC-5 and the MIC90; dash (−) indicates not determined.
bDetermined by partition coefficient
(n-octanol/water) (HPLC method).74
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from 13 to 67 μM, thereby resulting in low SI (<6.8) values and
making them less attractive candidates as antitubercular agents.56
The data obtained from MIC90 values under different condi-
tions (Table 2) indicated no significant differences between
MIC90 values under normal and others conditions. These condi-
tions included (a) adjusting the pH of the culture medium to 6.0,
(b) including 4% BSA, and (c) supplementing with 10% FBS.
The activity of antimicrobials is classified as containing narrow,
intermediate, or broad spectrum. Tuberculosis is a chronic
infection, the treatment of which requires a drug with a narrow
spectrum, such as INH. All amide-furoxan and benzofuroxan
(8, 11, 14, and 17) derivatives were checked against S. aureus,
E. coli, and C. albicans. No antimicrobial activity was detected
up to a maximum concentration of 200 μM.
In terms of cross-resistance, compound 8 displayed equipotent
activity (<2-fold change in MIC90) against all drug-sensitive and
monoresistant strains ofMtb tested, suggesting a novel MOA or
inhibition of a shared target containing a distinct binding site by
the compound (Table 3). In contrast, the amide-furoxan series
(4a−c) was inactive against half of the monoresistant strains
tested and therefore was not selected for further studies.
We utilized J774A.1, a macrophage cell line, to study the
intracellular inhibition of Mtb using the drugs under analysis.
We observed that compound 8 exhibited high intracellular
inhibition at all concentrations tested (around 90%). However,
similar to RMP, we could not verify the dose-dependent inhibi-
tion at different concentrations (Figure 2). In time−kill kinetic
experiments, compound 8 was observed to be bactericidal with
an early bactericidal effect. Noteworthy, compound 8 could
sterilize the cultures after 48 h of exposure (about of 6.7 log10;
Figure 3).
Preliminary ADMT Studies of Compound 8.On the basis
of the promising biological results described above for com-
pound 8, we conducted stability and ADMT studies to assess
its drug-like properties, such as absorption, distribution, and
metabolism. To analyze the chemical stability of the com-
pound, we conducted an in vitro assay under two pH conditions
(5.5 and 7.4) to mimic the environment of a macrophage phago-
lysosome (pH 4.5−6.2)72,73 and that of neutral plasma (pH 7.4).
At pH 5.5 and 7.4, compound 8 exhibited good stability
(Figure 4); however, a reduction of 20% was detected at both pH
values after 10 h. Interestingly, the concentration of compound 8
was 67 and 75% at pH 5.5 and 7.4, respectively, after 24 h.
The degradation rate of compound 8was calculated byHPLC-UV;
however, we did not characterize the degradation products.
These results indicated that compound 8 exhibited high stability
in the physiological pH range in the target areas of bacteria,
namely, blood and phagolysosome.
The in vitro ADMT properties of compound 8 are listed in
Table 4. The benzofuroxan derivative demonstrated a 46.5%
unbound fraction when an in vitro plasma protein binding assay
was conducted. The findings from the study of compound 8 on
the inhibition of cytochrome P450 isoforms indicated no poten-
tial for inhibition, presenting IC50 values greater than 15.0 μM
Table 2. MIC Determinations with Compound 8 against M. tuberculosis H37Rv (ATCC 27294) under Three Different
Conditions
normala acidic pHb FBSc BSAd
compound MIC (μM) SD MIC (μM) SD MIC (μM) SD MIC (μM) SD
8 5.47 1.01 3.41 1.52 11.79 0.93 9.81 1.21
rifampicin 0.05 0.03 0.02 0.02 0.10 0.08 0.10 0.03
aNormal: normal pH media (6.8). bAcidic pH: media pH adjusted to 6.0. cFBS: 10% fetal bovine serum. dBSA: 4% bovine serum albumin.
Table 3. Antitubercular Activity of N-Oxide-Containing Heterocycles against M. tuberculosis Monoresistant Strains
MIC (μM)
class compound INHra RMPra MOXra BDQra CAPra SMra
furoxan 4a >261.71 0.44 0.81 0.81 >261.71 27.4
4b >261.71 2.31 1.22 2.56 >261.71 >261.71
4c >261.71 1.99 0.66 6.38 >261.71 >261.71
benzofuroxan 8 8.59 3.78 5.72 1.20 15.25 16.98
standard drugs RIF 0.01 >1.00 0.10 0.04 0.21 0.03
INH >5.0 0.35 0.28 0.23 >5.00 >5.00
MOX 0.23 0.12 >8.00 0.26 0.35 0.36
BDQ 0.01 0.01 0.06 1.70 0.06 0.06
CAP − − − − 60.46 1.72
SM − − − − 2.55 >100
aINHr, isoniazid resistant; RMPr, rifampicin resistant; MOXr, moxifloxacin resistant; ,BDQr, bedaquiline resistant; CAPr, capreomycin resistant; and
SMr, streptomycin resistant. Dash (−) indicates not determined.
Figure 2. Intramacrophage activity of compound 8 and RMP after
infection of J774A.1 macrophages with M. tuberculosis H37Rv (ATCC
27294). The percentage of inhibition was determined as the mean of
three independent assays. The concentrations of the compounds were as
follows: compound 8: 23.86 μg/mL (4×MIC), 5.84 μg/mL (MIC), and
1.46 μg/mL (MIC/4); positive control (RMP): 0.064 μg/mL
(4× MIC), 0.016 μg/mL (MIC), and 0.04 μg/mL (MIC/4). Bars:
mean ± SD.
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against all isoforms tested. The studies in the Caco-2 cell line
demonstrated a good permeability profile. The cytotoxicity study
conducted in HepG2 cells reported an IC50 of 16.0 μM and an SI
of 14.5. We also performed the micronucleus assay using mouse
peripheral blood reticulocytes for compound 8 to evaluate its
intrinsic mutagenic activity. The results indicated that compound
8 was not genotoxic at any concentration tested (Figure 5).
Tolerability, Oral Bioavailability, and Efficacy of
Compound 8 in Mice. In vivo oral bioavailability, toxicology,
infection, and treatment studies were performed to ensure the
safety and efficacy of compound 8.
For toxicology studies, mice were monitored daily for 10 days,
receiving one daily oral dose (by gavage, 200 mg/kg body
weight), and their behavior parameters (hippocratic screening)
were evaluated. No significant variation in the behavior of mice
was observed during the period of 10 days. Changes in the weight
of organs (heart, lungs, spleen, kidneys, and liver) were evaluated
using analysis of variance (ANOVA) and Dunnett’s test,
establishing a p-value < 0.05 as the significant level. No statis-
tically significant difference was observed between the drug-
treated and control groups. To probe for potential liver damage,
the levels of liver transaminases were checked in the plasma and
indicated no significant differences for alanine aminotransferase
(Figure 6a), aspartate aminotransferase (Figure 6b), and alkaline
phosphatase (Figure 6c) between the treated and control groups.
Similarly, we evaluated the levels of urea in blood samples to
assess potential changes in kidney function. Here, a significant
difference was observed for the group treated with RMP-ME
when compared to the control group (Figure 6d). The study of
the oral bioavailability of compound 8 displayed an inhibition of
Mtb growth in mouse plasma (Table 5).
The histology of the liver (Figure 7) and kidneys (Figure 8)
revealed that the morphology of these tissues was the same in all
groups, implying that no gross abnormalities were caused by the
treatments.
The efficacy of compound 8was analyzed by infecting the mice
withMtb strainH37Rv followed by subjecting the infected animals
to the treatment with compound 8 or vehicle. The homogenized
lung samples were plated at dilutions of 1:100 to 1:10000, at
which no growth of Mtb colonies was observed. Therefore, the
homogenized lung samples were reinoculated on agar plates in
undiluted form and at 1:10 dilution; however, again, no colonies
were observed (Figure 9). Control experiments with vehicle,
RPM, and RPM-CE behaved as expected (Figure 9).
Mode of Action Studies. Although the antitubercular
activity of benzofuroxan derivative 8 was originally attributed to
its potential to generate and release nitric oxide (NO), we no
longer believe this to be the case because the compound could
not result in the release of NO in the Griess assay (a chemical test
to analyze nitrite ions in solution; data not shown). An alternative
mechanism was proposed as mentioned below.
Microarray analysis ofMtb treated with compound 8 or vehicle
control revealed a significant upregulation in the majority of
ribosomal genes as well as all genes encoding subunits of ATP
Figure 3. Time−kill curves of compound 8, rifampicin, isoniazid, and
moxifloxacin. Results are in log10 CFU/mL of M. tuberculosis H37Rv
(ATCC 27294) according to time (days). The CFU count was
determined as the mean of three independent assays. The concen-
trations of the compounds were 0.72 μM for INH, 0.01 μM for RMP,
0.88 μM for MOX, and 41.24 μM for compound 8. Bars: mean ± SD.
Figure 4. In vitro chemical stability. Hydrolytic profile of compound 8
in buffer (pH 5.5 and 7.4) (data are the mean ± SEM expressed as a
percentage).
Table 4. In Vitro ADMT Data for Compound 8
assay compound 8
human plasma protein binding (% free) 46.5
Caco-2 permeability
A−B Pappa (cm/s) 5.67 × 10−6
B−A Pappa (cm/s) 3.90 × 10−6
CYP inhibition IC50 (μM)
CYP2B6 >20
CYP2C8 >20
CYP2C19 15.3
CYP3A4 >20
HepG2 IC50 (μM) 16
aPapp is the apparent permeability rate coefficient.
Figure 5.Average frequency of micronucleated reticulocytes (MNRET)
and standard deviation of 1000 cells obtained frommice treated with the
positive control cyclophosphamide (50 mg/kg), CMC/Tween
(negative control), or compound 8 (50, 100, 200, and 500 mg/kg
body weight). *p < 0.05 (compared to negative control); **p < 0.05
(compared to the negative control and compound 8).
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01332
J. Med. Chem. 2017, 60, 8647−8660
8653
synthase (Figure 10 and Table S1). This included EF-G, which
induces GTP-dependent translocation of nascent peptide chains
from the A- to the P-site in the ribosome, and EF-Tu, which
promotes GTP-dependent binding of aminoacylated tRNAs to
the A-site in ribosomes. No upregulation of heat shock pro-
teins was observed; in fact, a downregulation of hsp, htrA, and
hspR was demonstrated (Table S1). Similarly, upregulation of
ribosomal proteins was observed upon treatment of Mtb with
inhibitors of protein synthesis. Our data indicated an upregu-
lation of a large number of operons aswell as single genes encoding
ribosomal proteins, which in turn suggested that compound 8
could affect protein synthesis by inhibiting the ribosome. Boshoff
and co-workers65 divided protein synthesis inhibitors into two
classes on the basis of their effect on the expression of heat shock
Figure 6. Alanine aminotransferase (a), aspartate aminotransferase (b), and alkaline phosphatase enzyme activity determinations (c) and urea
quantification (d) in the plasma of BALB/c mice. Each compound was administered at a daily oral dose (gavage) at a concentration of 200 mg/kg body
weight (n = 4 animals/group); RMPwas at a concentration of 20 mg/kg. Statistical analysis was performed using GraphPad Prism, version 5.01, through
ANOVA and Dunnett’s test, establishing P < 0.05 as the significance level. Bars: SD.
Table 5. Plasma Levels of Compound 8, RMP-ME, and RMP-CMC Following a Single Oral Administrationa
mouse datac
standardb 0.3 h 1 h 2 h 4 h
compound
MIC (μg/mL)
predetermined
drug dose
(mg/kg/body)
inhibition
(%)
estimate
(μg/mL)
inhibition
(%)
estimate
(μg/mL)
inhibition
(%)
estimate
(μg/mL)
inhibition
(%)
estimate
(μg/mL)
compound (8)-ME 5.84 300 65.67 42.61 79.00 51.26 76.00 49.31 51.33 33.30
RMP-ME 0.015 20 66.33 0.11 63.00 0.31 76.33 0.37 91.00 0.15
RMP-CMC 0.015 20 73.67 0.11 84.00 0.14 62.27 0.10 68.00 0.11
aExperiments were carried out in BALB/c mice. bPredetermined by the Resazurin microtiter assay (REMA) in vitro. cDetermined using mouse
plasma by REMA in vitro; estimates in plasma are given.
Figure 7. Histological section of liver stained with H&E from the group treated with compound 8. Histological sections stained with H&E showed, in
general, the presence of hepatocytes with polyhedral morphology, grouped in strings separated by sinusoids, forming well-defined hepatic lobes.
The sinusoids, characterized as wall capillaries coated by typical endothelial cells, had some Kupffer cells. In each border of the hepatic lobe there was the
presence of well-organized structures called portal spaces, which are characterized mainly by the presence of a portal hepatic vein (PHV), arteriole (A),
and bile duct (BD). This set was surrounded by a layer of intact and continuous connective tissue, which appeared to be cut off by channels that
discharged blood into the sinusoids, which flow into the central lobular vein.
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proteins (either no effect or upregulation). Compound 8 did not
increase the abundance of transcripts encoding heat shock
proteins and, in fact, decreased the levels of three transcripts (hsp,
htrA, and hspR). The results of this study of the inhibition of
protein synthesis indicated that compound 8 behaves more like
an inhibitor of translation initiation, such as tetracyclines, rather
than an inhibitor of protein synthesis that leads to mistranslation,
such as aminoglycosides. Further studies are required to define
the exact MOA of compound 8, including its binding site and
inhibition of the Mtb ribosome, ATP synthase, or other targets.
■ CONCLUSIONS
Twenty-two new N-oxide-containing compounds were synthe-
sized followed by in vitro and in vivo evaluation of their anti-
tubercular activity againstMtb. The amide-furoxan series (4a−c)
was observed to be the most promising compounds, with MIC90
values around 0.40 μM against actively replicating Mtb and SI
values ranging from 2033.3 to 3204.7. The benzofuroxan series
(8−17) also presented promising antitubercular activity, espe-
cially compound 8, which reported MIC90 values of 1.1 and
6.6 μM against actively growing and nonreplicatingMtb, respec-
tively. Compound 8 also displayed high activity in a macrophage
model of infection. In addition, in vivo studies employing amouse
model of infection demonstrated the sterilizing activity of com-
pound 8. No detectableMtb was observed in the lungs of treated
mice, whereas control mice displayed the expected number of
CFUs. Altogether, these findings highlight benzofuroxan deriv-
ative 8 as a novel lead compound for designing an antitubercular
drug that possesses sterilizing activity superior to that of rifampicin
in a mouse model of infection.
■ EXPERIMENTAL SECTION
Chemistry. Melting points (mp) were measured using an electro-
thermal melting point apparatus (SMP3; Bibby Stuart Scientific) or in
a Mettler FP82+FP80 apparatus (Greifense, Switzerland). Infrared
spectroscopy (KBr disc) was performed on a FTIR-8300 Shimadzu or a
Nicolet Nexu FTIR Thermo spectrometer, and the frequencies are
expressed in cm−1. NMR spectra for 1H and 13C of all compounds
were recorded on a Bruker Fourier spectrometer with a dual 13C/1H
(300 MHz) probe or a Bruker 400 Ultrashield 13C/1H (400 MHz)
spectrometer using deuterated chloroform (CDCl3) or dimethyl
sulfoxide (DMSO-d6) as solvent; the chemical shifts are expressed
in parts per million (ppm) relative to tetramethylsilane. The signal
multiplicities are reported as singlet (s), doublet (d), doublet of doublets
(dd), and multiplet (m). Elemental microanalysis (C, H, and N) was
performed on a PerkinElmer model 2400 analyzer or a CHN-900
Elemental Analyzer (LECO, Tres Cantos, Spain), and the data were
within ±0.4% of theoretical values. HRMS (ESI+) data were acquired
using a Bruker Maxis Impact quadrupole time-of-flight tandem mass
spectrometer (Q-TOF MS/MS), and the mass spectra values are
reported as m/z. The compounds were purified on a chromatography
column with silica gel (60 Å pore size, 35−75-μm particle size), and the
following solvents were used as the mobile phase: methanol, ethyl
acetate, dichloromethane, hexane, and petroleum ether in a flow rate of
approximately 20 mL/min. The reaction progress of all compounds was
monitored by thin-layer chromatography (TLC), which was performed
on 2.0 × 6.0 cm2 aluminum sheets precoated with silica gel 60 (HF-254;
Merck) to a thickness of 0.25 mm and revealed under UV light (265 nm).
All compounds were analyzed by HPLC, and their purity was confirmed
to be greater than 98.5%. HPLC conditions: Shimadzu HPLC model
CBM 20-A (Shimadzu) equipped with UV−vis detector (model SPD-
20A), quaternary pumping system mobile phase (model LC-20AT),
solvent degasser (model DGU-20As), and an Agilent Eclipse XDB C-18
column (250 mm× 27 4,6 mm; 5 μm). For HPLC, an isocratic flow was
used [methanol/water (75:25)]. Reagents and solvents were purchased
from commercial suppliers. Compounds 3a−c,45−47 7,48 18, 19, and
2854 were prepared according to previously described methods.
General Procedure for the Synthesis of Compounds 4a−c
and 8−17.A solution of compound 3a−c or 7 (0.87 mmol) in 10mL of
ethanol and 3 drops of glacial acetic acid was stirred at room tempera-
ture for 20 min. Next, the appropriate aromatic hydrazide (0.106 g,
0.87 mmol) was added, and the mixture was stirred for 12 h. The solvent
Figure 8.Histological section of kidneys stained with H&E from the group treated with compound 8. Histological sections stained with H&E generally
exhibited morphologically normal, well- functional units of the kidney. Each nephron had the Malpighi corpuscle, characterized by the following
structures: (1) Bowman’s capsule, formed by simple pavement epithelium, and (2) glomerulus (G), characterized by a set of capillaries of the fenestrated
type. Near theMalpighi corpuscle it was possible to observe proximal convoluted tubules formed by a simple layer of high cuboidal epithelial cells, which
have brush edges facing the lumen of the tubules. Also adjacent to the Malpighi corpuscles were distal tubules formed by low cuboidal cells.
Figure 9. Efficacy of compound 8 in microemulsion and controls
administrated once daily by oral gavage of a 200 μL suspension. Efficacy
of 200 mg/kg compound 8 against acute TB in mice. Female 20 g
BALB/cmicewere infected by aerosol with a lowdose (5× 106 CFU/mL)
ofM. tuberculosis Erdman. The start of treatment commenced at 10 days
postinfection and terminated at 29 days postinfection. Dosages were
obtained by once-daily dosing by oral gavage. Groups of 7 mice were
dosed for 5 consecutive days each week. CFU were determined after a
3 day washout period at day 31 postinfection. Both lungs were
homogenized and diluted in Hanks’ balanced salt solution (HBSS)-
Tween, and aliquots were plated on Middlebrook 7H11 medium. Bars:
SD. * indicates the effect of sterilization.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01332
J. Med. Chem. 2017, 60, 8647−8660
8655
was concentrated under reduced pressure, and ice was added to
precipitate the desired products. If necessary, the samples were further
purified by silica gel column chromatography using ethyl acetate/
methanol (98:2 v/v) as eluent to give the appropriate compound (4a−c
and 8−17) in variable yields.
(E)-3-Carbamoyl-4-((2-((2-isonicotinoylhydrazono)methyl)-
phenoxy)methyl)-1,2,5-oxadiazole 2-Oxide (4a). White powder;
yield, 51%; mp 226 to 229 °C. IR Vmax (cm
−1; KBr pellets): 3433
(NH2 amide), 3203 (N−H), 1669 (CO amide), 1587 (CN imine),
1456 (N−O furoxan), 1344 (C−N aromatic), 1145 (C−O ether). 1H
NMR (300 MHz, DMSO-d6, δ ppm) δ: 12.10 (1H; s; N−H), 8.79 (2H;
d), 8.51 (1H; s), 7.91 (1H; dd), 7.84 (2H; d), 7.46 (1H; m), 7.25 (1H;
d), 7.11 (1H; t), 5.54 (2H; s). 13C NMR (75 MHz, DMSO-d6, δ ppm)
δ: 161.55, 156.36, 155.65, 155.24, 150.30, 144.04, 140.47, 131.84,
125.85, 122.59, 121.87, 121.59, 113.36, 110.51. Anal. Calcd (%) for
C16H12N6O5: C: 52.18; H: 3.28; N: 22.82. Found: C: 52.25; H: 3.29;
N: 22.90. HRMS: m/z (ESI+) = 405.0918 [M + Na]+.
(E)-3-Carbamoyl-4-((3-((2-isonicotinoylhydrazono)methyl)-
phenoxy)methyl)-1,2,5-oxadiazole 2-Oxide (4b). White powder;
yield, 59%; mp 159 to 163 °C. IR Vmax (cm
−1; KBr pellets): 3439
(NH2 amide), 3201 (N−H), 1712 (CO amide), 1591 (CN imine),
1485 (N−O furoxan), 1327 (C−N aromatic), 1147 (C−O ether). 1H
NMR (300 MHz, DMSO-d6, δ ppm) δ: 12.09 (1H; s; N−H), 8.78 (2H;
d), 8.46 (1H; s), 7.81 (3H; d), 7.41 (3H; m), 5.48 (2H; s). 13C NMR
(75 MHz, DMSO-d6, δ ppm) δ: 156.96, 150.22, 147.97, 147.44, 142.63,
140.97, 132.70, 127.87, 122.48, 113.82, 113.14, 109.30, 105.24, 102.74.
Anal. Calcd (%) for C16H12N6O5: C: 52.18; H: 3.28; N: 22.82. Found:
C: 52.27; H: 3.29; N: 22.90. HRMS:m/z (ESI+) = 405.0922 [M +Na]+.
(E)-3-Carbamoyl-4-((4-((2-isonicotinoylhydrazono)methyl)-
phenoxy)methyl)-1,2,5-oxadiazole 2-Oxide (4c).White powder; yield,
67%; mp 235 to 239 °C. IR Vmax (cm
−1; KBr pellets): 3.367 (NH2
amide), 3255 (N−H), 1708 (CO amide), 1612 (CN imine), 1413
(N−O furoxan), 1255 (C−N aromatic), 1122 (C−O ether). 1H NMR
(300 MHz, DMSO-d6, δ ppm) δ: 11.95 (1H; s; N−H), 8.77 (2H; d),
8.43 (1H; s), 7.80 (2H; d), 7.71 (2H; d), 7.14 (2H; d), 5.48 (2H; s). 13C
NMR (75 MHz, DMSO-d6, δ ppm) δ: 162.96, 162.33, 159.91, 156.34,
150.86, 149.52, 141.14, 129.65, 128.08, 122.14, 115.84, 111.05. Anal.
Calcd (%) for C16H12N6O5: C: 52.18; H: 3.28; N: 22.82. Found:
C: 52.20; H: 3.28; N: 22.84. HRMS:m/z (ESI+) = 405.0913 [M +Na]+.
(E)-6-((2-Isonicotinoylhydrazono)methyl)benzo[c][1,2,5]-
oxadiazole 1-Oxide (8). Yellow powder; yield, 85%; mp 230 to 232 °C.
IR Vmax (cm
−1; KBr pellets): 3324 (N−H), 3045 (NH2 amide), 1690
(CO amide), 1600 (CN imine), 1409 (N−O furoxan), 1273 (C−N
aromatic). 1H NMR (300 MHz, DMSO-d6, δ ppm) δ: 12.44 (1H; s),
8.80 (2H; d; J = 5.7 Hz), 8.51 (1H; s), 8.03 (3H; m), 7.84 (2H; d; J =
6.0 Hz). 13C NMR (75 MHz, DMSO-d6, δ ppm) δ: 162.4, 150.6, 146.6,
140.2, 133.7, 130.8, 130.4, 130.1, 129.4, 121.8, 114.3. Anal. Calcd (%) for
C13H9N5O3: C: 55.13; H: 3.20; N: 24.73. Found: C: 55.22; H: 3.21;
N: 24.78. HRMS: m/z (ESI+) = 306.0602 [M + Na]+.
(E)-6-((2-Benzoylhydrazono)methyl)benzo[c][1,2,5]oxadiazole
1-Oxide (9). Yellow powder; yield, 80%;mp 220 to 221 °C. IRVmax (cm
−1;
KBr pellets): 3389 (N−H), 3041 (NH2 amide), 1641 (CO amide),
1533 (CN imine), 1487 (N−O furoxan), 1300 (C−N aromatic). 1H
NMR (300MHz, DMSO-d6, δ ppm) δ: 12.24 (1H; s), 8.52 (1H; s), 7.94
(5H; m), 7.58 (3H; m). 13C NMR (75 MHz, DMSO-d6, δ ppm) δ:
163.4, 145.0, 132.9, 132.1, 128.5, 127.8, 118.4, 113.5. Anal. Calcd (%) for
C14H10N4O3: C: 59.57; H: 3.57; N: 19.85. Found: C: 59.65; H: 3.56; N:
19.88.
(E)-6-((2-(4-(tert-Butyl)benzoyl)hydrazono)methyl)benzo[c]-
[1,2,5]oxadiazole 1-Oxide (10). Yellow powder; yield, 89%; mp 189 to
191 °C. IR Vmax (cm
−1; KBr pellets): 3341 (N−H), 3068 (NH2 amide),
1659 (CO amide), 1532 (CN imine), 1486 (N−O furoxan), 1287
(C−Naromatic). 1HNMR(300MHz,DMSO-d6, δppm) δ: 12.16 (1H; s),
8.51 (1H; s), 7.93 (4H; m), 7.56 (3H; d; J = 8.4 Hz), 1.32 (9H; s). 13C
NMR (75 MHz, DMSO-d6, δ ppm) δ: 160.3, 155.0, 144.7, 130.2, 127.7,
125.3, 118.3, 113.3, 56.0, 34.8, 30.9. Anal. Calcd (%) for C18H18N4O3:
C: 63.89; H: 5.36; N: 16.56. Found: C: 63.95; H: 5.37; N: 16.59.
(E)-6-((2-(4-Nitrobenzoyl)hydrazono)methyl)benzo[c][1,2,5]-
oxadiazole 1-Oxide (11). Yellow powder; yield, 78%; mp 261 to
262 °C. IR Vmax (cm
−1; KBr pellets): 3373 (N−H), 3073 (NH2 amide),
1673 (CO amide), 1525 (CN imine), 1400 (N−O furoxan), 1357
(C−Naromatic). 1HNMR(300MHz,DMSO-d6, δppm) δ: 12.50 (1H; s),
8.52 (1H; s), 8.39 (2H; d; J = 8.8 Hz), 8.17 (2H; d; J = 8.8 Hz), 7.95
(3H; m). 13C NMR (75 MHz, DMSO-d6, δ ppm) δ: 162.2, 149.4, 146.2,
138.7, 129.4, 123.7. Anal. Calcd (%) for C14H9N5O5: C: 51.38; H: 2.77;
N: 21.40. Found: C: 51.41; H: 2.77; N: 21.42.
(E)-6-((2-(2-Hydroxybenzoyl)hydrazono)methyl)benzo[c][1,2,5]-
oxadiazole 1-Oxide (12). Yellow powder; yield, 79%; mp 240 to
241 °C. IR Vmax (cm
−1; KBr pellets): 3573 (O−H), 3332 (N−H), 3100
Figure 10. Gene expression after 4 h of exposure to compound 8 at 2×MIC by microarray. (a) Heatmap and (b) volcano plot, illustrating the effect of
compound 8 versus vehicle on gene expression in M. tuberculosis H37Rv. (c) Table showing two examples of upregulated genes associated with the
ribosome or ATP synthase.
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(NH2 amide), 1638 (CO amide), 1532 (CN imine), 1484 (N−O
furoxan), 1341 (C−N aromatic). 1H NMR (300 MHz, DMSO-d6,
δ ppm) δ: 12.12 (1H; s), 11.64 (1H; s), 8.51 (1H; s), 7.95 (4H; m), 7.45
(1H; t; J = 7.5 Hz), 6.99 (2H; m). 13C NMR (75 MHz, DMSO-d6,
δ ppm) δ: 164.8, 158.7, 145.7, 134.0, 129.0, 119.1, 118.4, 117.3, 116.3,
113.7. Anal. Calcd (%) for C14H10N4O4: C: 56.38; H: 3.38; N: 18.79.
Found: C: 56.41; H: 3.37; N: 18.80.
(E)-6-((2-(3-Hydroxybenzoyl)hydrazono)methyl)benzo[c][1,2,5]-
oxadiazole 1-Oxide (13). Yellow powder; yield, 81%; mp 265 to
266 °C. IR Vmax (cm
−1; KBr pellets): 3578 (O−H), 3309 (N−H), 3118
(NH2 amide), 1643 (CO amide), 1532 (CN imine), 1371 (N−O
furoxan), 1293 (C−N aromatic). 1H NMR (300 MHz, DMSO-d6,
δ ppm) δ: 12.15 (1H; s), 9.80 (1H; s), 8.50 (1H; s), 7.99 (3H; m), 7.33
(3H; m), 7.00 (1H; d; J = 6.9 Hz). 13C NMR (75 MHz, DMSO-d6,
δ ppm) δ: 163.4, 157.4, 144.9, 134.3, 129.6, 119.0, 118.3, 114.6, 113.3.
Anal. Calcd (%) for C14H10N4O4: C: 56.38; H: 3.38; N: 18.79. Found:
C: 56.41; H: 3.38; N: 18.82.
(E)-6-((2-(4-Hydroxybenzoyl)hydrazono)methyl)benzo[c][1,2,5]-
oxadiazole 1-Oxide (14). Yellow powder; yield, 85%; mp 280 to
281 °C. IR Vmax (cm
−1; KBr pellets): 3573 (O−H), 3332 (N−H), 3096
(NH2 amide), 1638 (CO amide), 1523 (CN imine), 1371 (N−O
furoxan), 1280 (C−N aromatic). 1H NMR (300 MHz, DMSO-d6,
δ ppm) δ: 12.02 (1H; s), 10.21 (1H; s), 8.47 (1H; s), 8.01 (2H; m), 7.83
(2H; d; J = 8.7 Hz), 6.87 (3H; d; J = 8.7 Hz). 13C NMR (75 MHz,
DMSO-d6, δ ppm) δ: 163.0, 161.0, 152.8, 144.0, 136.3, 130.0, 128.8,
123.4, 118.2, 115.1, 114.8. Anal. Calcd (%) for C14H10N4O4: C: 56.38;
H: 3.38; N: 18.79. Found: C: 56.39; H: 3.39; N: 18.78.
(E)-6-((2-(2-Aminobenzoyl)hydrazono)methyl)benzo[c][1,2,5]-
oxadiazole 1-Oxide (15). Yellow powder; yield, 77%; mp 193 to
194 °C. IR Vmax (cm
−1; KBr pellets): 3501 (NH2 amine), 3319 (N−H),
3100 (NH2 amide), 1668 (CO amide), 1536 (CN imine), 1477
(N−O furoxan), 1346 (C−N aromatic). 1H NMR (300 MHz, DMSO-
d6, δ ppm) δ: 11.98 (1H; s), 8.44 (1H; s), 7.93 (3H; m), 7.59 (1H; d; J =
6.7 Hz), 7.22 (1H; t; J = 7.7 Hz), 6.76 (1H; d; J = 8.3 Hz), 6.58 (1H; d;
J = 7.0 Hz), 6.45 (2H; s). 13C NMR (75 MHz, DMSO-d6, δ ppm)
δ: 165.6, 152.8, 150.3, 143.8, 132.6, 128.5, 118.2, 116.5, 114.6, 112.7.
Anal. Calcd (%) for C14H11N5O3: C: 56.57; H: 3.73; N: 23.56. Found:
C: 56.64; H: 3.74; N: 23.58.
(E)-6-((2-(3-Aminobenzoyl)hydrazono)methyl)benzo[c][1,2,5]-
oxadiazole 1-Oxide (16). Yellow powder; yield, 82%; mp 213 to
215 °C. IR Vmax (cm
−1; KBr pellets): 3501 (NH2 amine), 3232 (N−H),
3100 (NH2 amide), 1638 (CO amide), 1532 (CN imine), 1416
(N−O furoxan), 1312 (C−N aromatic). 1H NMR (300 MHz, DMSO-
d6, δ ppm) δ: 12.31 (1H; s), 8.86 (1H; s), 8.53 (1H; s), 8.10 (3H; m),
7.87 (3H; s), 7.64 (1H; t; J = 7.9 Hz), 7.57 (1H; d; J = 7.3 Hz). 13CNMR
(75 MHz, DMSO-d6, δ ppm) δ: 162.9, 159.6, 150.5, 148.9, 145.2, 134.1,
129.7, 128.9, 126.3, 124.6, 120.7, 114.7. Anal. Calcd (%) for
C14H11N5O3: C: 56.57; H: 3.73; N: 23.56. Found: C: 56.59; H: 3.73;
N: 23.59.
(E)-6-((2-(4-Aminobenzoyl)hydrazono)methyl)benzo[c][1,2,5]-
oxadiazole 1-Oxide (17). Yellow powder; yield, 84%; mp 218 to
200 °C. IR Vmax (cm
−1; KBr pellets): 3478 (NH2 amine), 3319 (N−H),
3118 (NH2 amide), 1627 (CO amide), 1500 (CN imine), 1380
(N−O furoxan), 1252 (C−N aromatic). 1H NMR (300 MHz, DMSO-
d6, δ ppm) δ: 8.44 (1H; s), 7.92 (3H; m), 7.69 (2H; d; J = 8.6 Hz), 6.60
(2H; d; J = 8.6 Hz), 5.87 (2H; s). 13C NMR (75 MHz, DMSO-d6,
δ ppm) δ: 165.3, 152.6, 142.9, 129.7, 118.9, 112.6. Anal. Calcd (%) for
C14H11N5O3: C: 56.57; H: 3.73; N: 23.56. Found: C: 56.58; H: 3.74;
N: 23.57.
General Procedure for the Synthesis of Compounds 20−26.
Compound 18 (0.3 g, 1.06 mmol) was dissolved in dichloromethane
(15 mL) and then cooled by placing it on an ice bath. Next, the appro-
priate nitrile (0.15 g, 1.06 mmol) and potassium carbonate (0.18 g,
1.32 mmol) were added in small portions. The reaction mixture was
stirred at 40 °C for 96 h. Afterward, the solvent was evaporated under
reduced pressure and the obtained solid was dissolved in 50 mL of ethyl
acetate and washed with water. The organic phase was dried with
anhydrous magnesium sulfate, and the solvent was evaporated, giving a
yellow solid. The obtained solid was purified by silica gel column
chromatography using hexane and ethyl acetate (70:30 v/v) as eluent to
give the appropriate compound (20−26) in variable yields.
3-Cyano-6-(1,3-dioxolan-2-yl)-2-(p-tolyl)quinoxaline 1,4-Dioxide
(20). Yellow powder; yield, 9%; mp 179 to 180 °C. IR Vmax (cm
−1; KBr
pellets): 3090 (C−H aromatic), 2233 (CN nitrile), 1328 (N−O), 1073
(C−O ether). 1H NMR (400 MHz, DMSO-d6, δ ppm) δ: 8.55 (2H; t;
J = 18.7Hz), 8.12 (1H; d; J = 8.8Hz), 7.63 (2H; d; J = 8.0Hz), 7.43 (2H;
d; J = 7.9 Hz), 6.10 (1H; s), 4.09 (4H; m), 2.43 (3H; s). 13C NMR
(75 MHz, DMSO-d6, δ ppm) δ: 143.1, 143.0, 141.1, 136.7, 132.2, 130.1,
129.2, 129.1, 124.7, 121.0, 117.7, 101.1, 65.3, 21.1. Anal. Calcd (%) for
C19H15N3O4: C: 65.32; H: 4.33; N: 12.03. Found: C: 65.36; H: 4.32;
N: 12.05.
2-(4-Chlorophenyl)-3-cyano-6-(1,3-dioxolan-2-yl)quinoxaline
1,4-Dioxide (21). Yellow powder; yield, 13%; mp 177 to 178 °C. IR Vmax
(cm−1; KBr pellets): 3091 (C−H aromatic), 2235 (CN nitrile), 1330
(N−O), 1093 (C−O ether). 1H NMR (400 MHz, DMSO-d6, δ ppm)
δ: 8.56 (2H; t; J = 16.0 Hz), 8.12 (1H; dd; J = 26.5 Hz), 7.75 (4H; q; J =
25.4 Hz), 6.11 (1H; s), 4.09 (4H; m). 13C NMR (75 MHz, DMSO-d6,
δ ppm) δ: 144.8, 142.1, 138.8, 137.1, 136.0, 132.1, 130.8, 128.8, 126.5,
121.1, 117.7, 65.3. Anal. Calcd (%) for C18H12ClN3O4: C: 58.47;
H: 3.27; N: 11.36. Found: C: 58.67; H: 3.36; N: 11.53.
3-Cyano-6-(1,3-dioxolan-2-yl)-2-(4-methoxyphenyl)quinoxaline
1,4-Dioxide (22). Yellow powder; yield, 26%; mp 151 to 152 °C. IR Vmax
(cm−1; KBr pellets): 3085 (C−H aromatic), 2236 (CN nitrile), 1335
(N−O), 1095 (C−O ether). 1H NMR (400 MHz, DMSO-d6, δ ppm)
δ: 8.55 (2H; m), 8.05 (1H; dd), 7.71 (2H; d; J = 8.8 Hz), 7.17 (2H; d; J =
8.7 Hz), 6.09 (1H; s), 4.08 (4H; m), 3.87 (3H; s). 13C NMR (75 MHz,
DMSO-d6, δ ppm) δ: 161.2, 144.6, 142.9, 138.8, 132.4, 132.0, 120.6,
119.3, 118.0, 117.7, 113.9, 101.1, 65.2, 55.4. Anal. Calcd (%) for
C19H15N3O5: C: 62.46; H: 4.14; N: 11.50. Found: C: 62.51; H: 4.15;
N: 11.52.
3-Cyano-6-(1,3-dioxolan-2-yl)-2-(4-fluorophenyl)quinoxaline 1,4-
Dioxide (23). Yellow powder; yield, 30%; mp 164 to 165 °C. IR Vmax
(cm−1; KBr pellets): 3077 (C−H aromatic), 2234 (CN nitrile), 1330
(N−O), 1097 (C−O ether). 1H NMR (400 MHz, DMSO-d6, δ ppm)
δ: 8.56 (2H; t; J = 17.5 Hz), 8.15 (1H; d; J = 10.4 Hz), 7.81 (2H; t; J =
14.1 Hz), 7.49 (2H; t; J = 17.7 Hz), 6.10 (1H; s), 4.09 (4H; m). 13C
NMR (75 MHz, DMSO-d6, δ ppm) δ: 162.2, 143.2, 142.3, 139.1, 136.7,
133.0, 132.9, 132.3, 124.0, 121.0, 117.7, 115.7, 101.0, 65.3. Anal. Calcd
(%) for C18H12FN3O4: C: 61.19; H: 3.42; N: 11.89. Found: C: 61.18;
H: 3.41; N: 11.90.
3-Cyano-6-(1,3-dioxolan-2-yl)-2-(4-(trifluoromethoxy)phenyl)-
quinoxaline 1,4-Dioxide (24). Yellow powder; yield, 3%; mp 186 to
187 °C. IR Vmax (cm
−1; KBr pellets): 3077 (C−H aromatic), 2236 (CN
nitrile), 1333 (N−O), 1165 (C−O ether). 1HNMR (400MHz, DMSO-
d6, δ ppm) δ: 8.57 (2H; t; J = 15.4 Hz), 8.15 (1H; d; J = 8.9 Hz), 7.89
(2H; d; J = 8.7 Hz), 7.66 (2H; d; J = 8.4 Hz), 6.11 (1H; s), 4.10 (4H; m).
13C NMR (75 MHz, DMSO-d6, δ ppm) δ: 149.9, 143.3, 141.9, 139.1,
136.8, 132.7, 132.4, 131.0, 126.7, 121.3, 121.0, 120.9, 117.7, 101.0, 65.3.
Anal. Calcd (%) for C19H12F3N3O5: C: 54.42; H: 2.88; N: 10.02. Found:
C: 54.47; H: 2.88; N: 10.06.
3-Cyano-6-(1,3-dioxolan-2-yl)-2-(furan-2-yl)quinoxaline 1,4-Di-
oxide (25). Orange powder; yield, 26%; mp 177 to 179 °C. IR Vmax
(cm−1; KBr pellets): 3087 (C−H aromatic), 2240 (CN nitrile), 1355
(N−O), 1107 (C−O ether). 1H NMR (300 MHz, DMSO-d6, δ ppm)
δ: 8.57 (1H; dd; J = 5.2, 3.6 Hz), 8.49 (1H; d; J = 8.9 Hz), 8.24 (2H; d;
J = 3.5 Hz), 8.01 (1H; dd; J = 8.9, 1.6 Hz), 6.95 (1H; dd; J = 3.6, 1.8 Hz),
6.08 (1H; d; J = 3.1 Hz), 4.09 (4H; m). 13C NMR (75 MHz, DMSO-d6,
δ ppm) δ: 146.8, 144.7, 142.3, 140.2, 138.5, 135.6, 133.4, 132.3, 130.0,
120.9, 117.7, 116.8, 113.2, 111.1, 101.2, 65.3. Anal. Calcd (%) for
C16H11N3O5: C: 59.08; H: 3.41; N: 12.92. Found: C: 59.12; H: 3.42;
N: 12.94.
3-Cyano-6-(1,3-dioxolan-2-yl)-2-(thiophen-2-yl)quinoxaline 1,4-
Dioxide (26). Brown powder; yield, 15%; mp 171 to 173 °C. IR Vmax
(cm−1; KBr pellets): 3092 (C−H aromatic), 2241 (CN nitrile), 1357
(N−O), 1084 (C−O ether). 1H NMR (300 MHz, DMSO-d6, δ ppm)
δ: 8.60 (1H; dd; J = 5.3, 3.6 Hz), 8.51 (1H; d; J = 8.8 Hz), 8.45 (1H; dt;
J = 4.2, 1.2 Hz), 8.13 (1H; dd; J = 5.1, 1.0 Hz), 8.03 (1H; dd; J = 8.9,
1.7 Hz), 7.43 (1H; dd; J = 5.0, 4.2 Hz), 6.09 (1H; d; J = 3.8 Hz), 4.09
(4H; m). 13C NMR (75 MHz, DMSO-d6, δ ppm) δ: 145.1, 142.5, 138.1,
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137.7, 136.8, 135.6, 132.5, 130.2, 127.0, 126.0, 120.7, 117.9, 112.6, 101.2,
65.1. Anal. Calcd (%) for C16H11N3O4S: C: 56.30; H: 3.25; N: 12.31.
Found: C: 56.31; H: 3.25; N: 12.30.
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